9amHealth, Instacart tackle obesity with healthy food and GLP-1s: We think that employer and health plan customers will be pleased with the program’s less costly approach than prescription weight loss drugs alone.

Elevance, doctors quarrel over volume of Ozempic prescriptions: The insurer doesn’t want to cover Ozempic to treat obesity. But are healthcare providers the ones to blame?

Noom gets into compounded GLP-1s with a taper-off guarantee: It’s building a weight loss program around the idea that patients will eventually want to stop taking the medications. We explore the pros and cons.

The Ozempic effect could have wide-ranging implications beyond the food industry—if it exists: Apparel makers, beauty brands, and airlines could capitalize as GLP-1 adoption grows, but only if users stick to the meds.

WeightWatchers enters the Rx business for obesity: Its acquisition of medication-based weight loss program Sequence signals an emerging digital health market trend—but consumers must be cautious of telehealth startups' claims.